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ABSTRACT
Background Long-term antibiotic therapy is used to
prevent exacerbations of COPD but there is uncertainty
over whether this reduces airway bacteria. The optimum
antibiotic choice remains unknown. We conducted an
exploratory trial in stable patients with COPD comparing
three antibiotic regimens against placebo.
Methods This was a single-centre, single-blind,
randomised placebo-controlled trial. Patients aged
≥45 years with COPD, FEV1<80% predicted and chronic
productive cough were randomised to receive either
moxiﬂoxacin 400 mg daily for 5 days every 4 weeks,
doxycycline 100 mg/day, azithromycin 250 mg 3 times a
week or one placebo tablet daily for 13 weeks. The
primary outcome was the change in total cultured
bacterial load in sputum from baseline; secondary
outcomes included bacterial load by 16S quantitative
PCR (qPCR), sputum inﬂammation and antibiotic
resistance.
Results 99 patients were randomised; 86 completed
follow-up, were able to expectorate sputum and were
analysed. After adjustment, there was a non-signiﬁcant
reduction in bacterial load of 0.42 log10 cfu/mL (95% CI
−0.08 to 0.91, p=0.10) with moxiﬂoxacin, 0.11 (−0.33
to 0.55, p=0.62) with doxycycline and 0.08 (−0.38 to
0.54, p=0.73) with azithromycin from placebo,
respectively. There were also no signiﬁcant changes in
bacterial load measured by 16S qPCR or in airway
inﬂammation. More treatment-related adverse events
occurred with moxiﬂoxacin. Of note, mean inhibitory
concentrations of cultured isolates increased by at least
three times over placebo in all treatment arms.
Conclusions Total airway bacterial load did not
decrease signiﬁcantly after 3 months of antibiotic
therapy. Large increases in antibiotic resistance were
seen in all treatment groups and this has important
implications for future studies.
Trial registration number clinicaltrials.gov
(NCT01398072).
INTRODUCTION
COPD exacerbations are important events asso-
ciated with poorer health status,1 lung function
decline2 and mortality.3 Their prevention is an
important goal of COPD treatment4 5 which is not
currently met by existing inhaled therapies.6 7
Exacerbation frequency is linked to airway bac-
terial colonisation during the stable state,8 and
long-term antibiotic therapy has been proposed to
prevent exacerbations. The best evidence for this
comes from the macrolide antibiotics, with both
erythromycin9 and azithromycin10 shown to signiﬁ-
cantly reduce exacerbation frequency although at
the expense of auditory decrements and a possible
increase in cardiovascular risk.11 There is less evi-
dence for other antibiotic classes in stable COPD,
although the ﬂuoroquinolone moxiﬂoxacin has
shown some efﬁcacy when used in a pulsed dosing
regimen,12 and with no comparative studies there
are few data to inform the optimum antibiotic
choice. There are also growing concerns regarding
the development of antibiotic resistance in airway
bacteria.13
Although the presumptive mode of action of
antibiotics is via reducing airway bacterial load, no
trials to date have examined this in stable COPD.
Furthermore, molecular techniques are now
important tools in accurately quantifying the
airway microbiome14 and may be able to detect
more subtle changes with therapy than traditional
culture-based methods.
For the ﬁrst time, we aimed to directly compare
the effects of different antibiotics on airway
Key messages
What is the key question?
▸ How do three different antibiotics
(moxiﬂoxacin, doxycycline and azithromycin)
compare in their effects on total airway
bacterial load in stable COPD?
What is the bottom line?
▸ Airway bacterial load was similar to placebo
after treatment with all three antibiotics,
although increases in antimicrobial resistance
were noted in all treatment arms.
Why read on?
▸ This is the ﬁrst trial to directly compare the
effects of different antibiotic classes on airway
bacterial load in stable COPD.
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bacterial load in patients with stable COPD, measured both by
culture and 16S quantitative PCR (qPCR). We also examined
important secondary clinical endpoints, bacterial resistance and
changes in airway inﬂammation.
METHODS
Study design
This was an exploratory 13-week, single-centre, single-blind,
placebo controlled, randomised controlled trial conducted at the
Royal Free Hospital (London, UK). We compared the efﬁcacy of
pulsed moxiﬂoxacin 400 mg daily for 5 days every 4 weeks,
doxycycline 100 mg daily, azithromycin 250 mg three times per
week, or placebo one tablet daily, at reducing bacterial numbers
in spontaneously expectorated sputum after 13 weeks of
treatment.
Research ethics approval was granted by King’s College
Regional Ethics Committee (reference 11/LO/0932).
Participants
Subjects were recruited from primary and secondary care;
further details can be found in the online supplementary data.
Screening and all study visits took place in the outpatient
department at the Royal Free Hospital, London. Sputum pro-
cessing and culture, sensitivity testing and inﬂammatory marker
analysis were conducted in the laboratories of the Centre for
Respiratory Medicine and the Centre for Clinical Microbiology,
Royal Free Campus, University College London. DNA extrac-
tion and 16S qPCR were conducted in the laboratories of the
National Heart and Lung Institute, Imperial College London.
Inclusion and exclusion criteria
Stable patients aged ≥45 years with chronic bronchitis (self-
reported sputum expectoration on most days when clinically
stable) and spirometrically conﬁrmed COPD (deﬁned by
FEV1<80% predicted, FEV1 to FVC ratio <0.7 and a history
of smoking) were included. Patients who reported either treat-
ment for an exacerbation or an episode of symptom worsening
in the 4 weeks prior to screening, or were unable to enrol for
safety reasons, were excluded. Detailed inclusion and exclusion
criteria can be found in the online supplementary data.
Screening and run-in period
After clinical assessment, spirometry was performed in accord-
ance with American Thoracic Society/European Respiratory
Society guidance15 using a Vitalograph Gold Standard spirom-
eter (Vitalograph, Maids Morton, UK). Spontaneously expecto-
rated sputum was collected for analysis prior to randomisation.
Patients also completed the St George’s Respiratory
Questionnaire (SGRQ) to assess health status. Patients received
diary cards and recorded any worsening of their respiratory
symptoms each day for a 1-week run-in period; these have pre-
viously been shown to be a reliable index of exacerbation.16
Randomisation and masking
Patients returned to the clinic 1 week after screening. The diary
cards and screening results were checked and details sought
regarding any adverse events. If the subject remained eligible
and clinically stable after reassessment, and had been able to
provide a sputum sample for analysis by the second visit, then
internet randomisation into groups of 1:1:1:1 was performed
using a computer-generated permuted block system of variable
sizes (Sealed Envelope, UK). Patients remained blinded to treat-
ment allocation.
Follow-up of patients
Patients were telephoned by the study doctor during weeks 5
and 9 of treatment and any adverse events or exacerbations
recorded. Patients who suffered a COPD exacerbation during
the trial were treated either by their treating physician or using
self-administered treatment as appropriate; exacerbation treat-
ment during the study was not standardised. To avoid drug
interactions, the study medication was temporarily stopped if
the patient took other antibiotics for any reason. Details of
exacerbations were recorded on the daily diary cards and the
study team notiﬁed.
Patients attended the clinic at the end of 13 weeks of treat-
ment. A further spontaneously expectorated sputum sample was
collected and the SGRQ administered, diary cards collected and
any exacerbations or adverse events recorded. Unused medica-
tion was collected and pill counts performed for adherence
analysis.
Outcome measures
The primary outcome was the change in sputum bacterial load,
as assessed by quantitative culture. Prespeciﬁed secondary out-
comes were changes in resistance to the three tested antibiotics,
changes in FEV1, adherence to therapy, health status as mea-
sured by total SGRQ scores and adverse events. Further explora-
tory outcomes assessed changes in sputum bacterial load as
assessed by 16S rRNA gene targeted qPCR and changes in
sputum inﬂammation.
Laboratory analysis of sputum
A minimum of 0.25 g spontaneously expectorated sputum was ana-
lysed using a modiﬁcation of the method described by Pye et al.17
Mean inhibitory concentrations (MICs) were established for
each isolate against each of the three antibiotics by Etest
(bioMérieux UK, Basingstoke, UK) and isolates were deﬁned as
sensitive, intermediate or resistant where breakpoints were
available.
DNA was isolated from sputum and qPCR for 16S bacterial
ribosomal RNA gene carried out using a ViiA 7 real-time PCR
system (Life Technologies, Paisley, UK).
Sputum supernatant was batch analysed for the cytokines
interleukin (IL)-6, IL-8 and IL-1β using commercial high-
sensitivity sandwich ELISA kits (RD Systems, Abingdon, UK).
The lower limits of detection were 0.70, 3.5 and <1.0 pg/mL,
respectively.
Further detail on these methods is included in the online sup-
plementary data.
Statistical analysis
Pre-existing comparative data showing the effect of antibiotics
on sputum bacterial numbers using quantitative culture methods
were unavailable. Using PCR analysis, data from within our
group showed that, in patients demonstrating bacterial colonisa-
tion on ≥2 occasions, mean (SD) sputum bacterial load when
stable was 6.89 (1.23) log10 cfu/mL, falling to 5.01 (3.71) after
antibiotic treatment at exacerbation. Assuming a correlation of
0.5 between the baseline and 3-month follow-up measurements,
we calculated that 44 patients in each of the four groups would
be sufﬁcient to have a 90% chance of detecting, as signiﬁcant at
the 5% level, a difference between untreated (placebo) and post-
treatment bacterial load of 1.88 log10 cfu/mL.
Analysis was by intention to treat. The primary endpoint of
total bacterial numbers in sputum (the sum of the bacterial load
for each isolate cultured from a sample) was analysed using
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multiple regression after log10 transformation to assess the treat-
ment effect for each antibiotic compared with placebo. Where
growth was below the limit of detection (6×106 cfu/mL), patients
were treated as having a left-censored outcome and a parametric
survival regression model was used. Spirometry, health status
(SGRQ) and adherence to therapy were modelled using linear,
Poisson or logistic regression as appropriate. Antibiotic resistance
was modelled using a linear mixed effects model for log(MIC) to
account for multiple detected isolates within each individual; a
generalised mixed effects model was used to analyse resistance as a
binary outcome. All analyses were adjusted for baseline values,
with multivariable analyses further adjusted for age, sex, current
smoking status, FEV1% predicted and previous exacerbation
history. Exacerbations during the study period were deﬁned using
diary card criteria as previously reported18 as well as patient
reporting to clinical health professionals or the study team, with
the ﬁnal decision made by consensus. A further methodological
analysis compared the measurement techniques of quantitative
culture and 16S qPCR using the Bland–Altman method19 for all
samples where both results were available.
RESULTS
Patient characteristics at recruitment
Two hundred and forty-eight patients were screened between
February 2012 and May 2013; 99 were randomised, and
sputum was analysed for the primary endpoint from 86.
Figure 1 shows the screening, randomisation and follow-up of
patients. Patient characteristics at baseline are summarised in
table 1. This cohort of patients was representative of the popu-
lation with moderate–severe COPD, with a male preponderance,
overall mean age of 69·5 years and mean FEV1 50·5%
predicted.
Primary endpoint: bacterial numbers
In an analysis of bacterial load, adjusted only for baseline
values, there was a mean change of −0·32 log10 cfu/mL (95%
CI −0.81 to 0.17, p=0.20) from placebo in the moxiﬂoxacin
arm, −0·05 (95% CI −0.50 to 0.40, p=0.82) in the doxycycline
arm and −0.17 (95% CI −0.62 to 0.29, p=0.47) in the azithro-
mycin arm. The largest change in bacterial numbers was there-
fore seen with moxiﬂoxacin, equivalent to a 62% reduction,
although this was not statistically signiﬁcant at the 5% level.
The smallest change was seen with azithromycin. These results
are summarised in table 2.
A total of 395 isolates were cultured: 222 at study start and
173 after treatment. The most common isolates were
Streptococcus spp other than Streptococcus pneumoniae.
Figure 2 shows the species breakdown of these isolates.
Secondary and exploratory endpoints
Bacterial numbers by 16S qPCR
One hundred and forty-two paired samples from 71 patients
were available for this analysis. As with quantitative culture,
there were no signiﬁcant changes in overall bacterial load com-
pared with placebo in any of the antibiotic treatment arms
(table 2).
Sputum inﬂammatory markers
These were also measured in the subset of patients where extra
paired sputum samples were available (n=71). No signiﬁcant
Figure 1 CONSORT diagram for this study showing screening, patient recruitment and data ﬂow for the primary endpoint.
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changes were seen in any of the three measured cytokines IL-6,
IL-8 and IL-1β in any of the antibiotic treatment arms compared
with placebo (table 2).
Bacterial resistance
Two hundred and forty-three isolates from 69 patients where
≥1 isolate was cultured both pre and post treatment were tested
for bacterial resistance. There were measurable increases in the
degree of antibiotic resistance of isolates in all three antibiotic
arms. After adjusting for baseline MIC and whether the isolate
was a species known to be associated with lower respiratory
tract infection, moxiﬂoxacin was associated with a factor
increase in MIC of 4.82 (95% CI 1.44 to 16.19, p=0.01),
doxycycline 3·74 (95% CI 1.46 to 9.58, p=0.01) and azithro-
mycin 6.23 (95% CI 1.66 to 23.35, p=0.01) for isolates cul-
tured in sputum taken from patients assigned to those
antibiotics compared with placebo. Modelling the number of
resistant isolates (where MIC break points were available for
speciﬁc isolates to speciﬁc antibiotics), isolates from patients in
the doxycycline group were more likely to be resistant to doxy-
cycline than placebo (OR 5.77 (95% CI 1.40 to 23.74,
p=0.02)). ORs for the other antibiotics were also >2 but these
were not statistically signiﬁcant. Boxplots demonstrating the
mean MIC concentrations are shown in ﬁgure 3.
Lung function
There was a mean increase in FEV1 compared with placebo of
40 mL with moxiﬂoxacin, 30 mL with doxycycline and 0 mL
with azithromycin, although these changes were not signiﬁcant
at the 5% level, even after further adjustment (table 2).
Health status
The changes in SGRQ total score are listed in table 2. After
adjustment, the largest improvement was seen with azithromycin
compared with placebo, but these changes were again not sig-
niﬁcant at the 5% level.
Adherence to therapy
Adherence to therapy was high in all treatment arms (mean
(SD) adherence 95%,13 93%,20 96%11 and 95%9 for moxiﬂox-
acin, doxycycline, azithromycin and placebo, respectively). No
signiﬁcant differences were detected between groups (table 2).
Exacerbations
During the study, 41 patients experienced 81 distinct exacerba-
tions (21 on moxiﬂoxacin, 32 on doxycycline, 13 on azithromy-
cin and 15 on placebo). The relative risks of exacerbation are
shown in table 2; there was an indication of increased exacerba-
tions in the doxycycline group, although there was a small
number of patients in the doxycycline and moxiﬂoxacin groups
who reported frequent exacerbations during the study period.
Figure 4 shows the number of exacerbations by treatment
group.
Adverse events
The highest number of treatment-related adverse events, 10
(40%), was reported with moxiﬂoxacin therapy. These were pre-
dominantly minor; therapy was withdrawn in four cases. There
were two treatment-related adverse events reported with doxy-
cycline and one with azithromycin. There were no
treatment-related serious adverse events or suspected unex-
pected serious adverse reactions. Further detail is contained in
the supplementary data.
Comparison of airway load measurements using quantitative
culture and 16S qPCR
Across all samples measured by both methods, 16S qPCR
detected 10-fold more bacteria than quantitative culture
Table 1 Patient characteristics at baseline (mean (SD) unless stated)
Treatment group Moxifloxacin Doxycycline Azithromycin Placebo
Total (n) 25 25 25 24
Gender (n, % male) 17 (68) 18 (72) 16 (64) 18 (75)
Age (years) 70.9 (8.2) 70.4 (7.0) 67.9 (8.6) 68.7 (9.8)
BMI (kg/m2) 26.3 (5.2) 28.4 (6.4) 26.6 (6.9) 26.9 (4.9)
Current smoker, n (%) 16 (64) 10 (40) 7 (28) 8 (33)
Pack-years 53 (27) 52 (50) 51 (25) 56 (50)
Number of exacerbations in previous year* 2.5 (2.1) 2.1 (1.7) 2.8 (4.0) 1.5 (1.4)
Inhaled corticosteroid use, n (%) 21 (84) 19 (76) 18 (72) 13 (57)
Bacterial load, log10 cfu/mL† 8.3 (0.8) 8.1 (0.7) 8.1 (0.8) 7.8 (0.7)
Bacterial load, log10 16S copies/g sputum 9.4 (0.8) 9.3 (0.73) 9.0 (0.6) 9.1 (0.8)
FEV1 (L) 1.4 (0.5) 1.5 (0.5) 1.2 (0.5) 1.5 (0.6)
FEV1:FVC 0.51 (0.10) 0.51 (0.13) 0.45 (0.12) 0.51 (0.12)
FEV1, % predicted 52 (13) 53 (14) 44 (17) 53 (13)
FVC (L) 2.8 (1.1) 3.0 (1.1) 2.7 (0.7) 3.0 (1.0)
SGRQ: total score 51 (14) 47 (16) 48 (18) 46 (19)
SGRQ: symptom score 64 (16) 62 (24) 59 (18) 55 (19)
SGRQ: activity score 67 (21) 62 (19) 66 (25) 61 (24)
SGRQ: impact score 37 (12) 35 (16) 35 (18) 34 (20)
Il-1β, log10 pg/mL 2.3 (0.6) 1.9 (0.7) 2.2 (0.8) 2.1 (0.7)
IL-6, log10 pg/mL 1.9 (0.7) 1.5 (0.8) 1.8 (0.8) 1.6 (0.6)
IL-8, log10 pg/mL 4.3 (0.7) 3.9 (0.9) 4.1 (0.7) 3.8 (0.8)
*Self-reported exacerbation frequency.
†For those patients with culture results above the threshold of detection.
BMI, body mass index; IL, interleukin; SGRQ, St George’s Respiratory Questionnaire.
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(excluding samples where no organisms were detected on
culture, n=13) (mean (SD) 9.15 (0.79) log10 copies/mL vs 8.12
(0.71) log10 cfu/mL, p<0.001). There was a signiﬁcant correl-
ation between the two techniques (Pearson’s r=0.465,
p<0.001). Comparison of the measurement techniques using a
Bland–Altman plot showed a 3.5-log variation in the measure-
ment differences, although there was no proportional bias
across the measured range of values (ﬁgure 5).
DISCUSSION
This study, for the ﬁrst time, reports on the direct comparison
of 13 weeks of therapy using different antibiotic classes and dif-
ferent measurement techniques against the endpoint of airway
bacterial load in stable COPD. Most notably, there were no sig-
niﬁcant reductions in sputum bacterial load, by culture or
qPCR, with any of these three antibiotics compared with
placebo. Although pulsed moxiﬂoxacin demonstrated the largest
Table 2 Primary and secondary outcome measures for this study
Drug
Estimated change from placebo
Baseline adjusted estimate
(95% CI), p value
Fully adjusted* estimate
(95% CI), p value
Bacterial load by quantitative culture (log10 cfu/mL)
Moxifloxacin −0.32 (−0.81 to 0.17) p=0.20 −0.42 (−0.91 to 0.08) p=0.10
Doxycycline −0.05 (−0.50 to 0.40), p=0.82 −0.11 (−0.55 to 0.33), p=0.62
Azithromycin −0.17 (−0.62 to 0.29), p=0.47 −0.08 (−0.54 to 0.38), p=0.73
Bacterial load by 16S qPCR (log10 copies/g of sputum)
Moxifloxacin 0.14 (−0.42 to 0.69), p=0.63 0.30 (−0.30 to 0.89), p=0.33
Doxycycline 0.06 (−0.49 to 0.60), p=0.84 0.16 (−0.40 to 0.72), p=0.58
Azithromycin 0.28 (−0.27 to 0.83), p=0.33 0.32 (−0.24 to 0.88), p=0.27
FEV1, mL
Moxifloxacin 39 (−84 to 161), p=0.54 58 (−74 to 190), p=0.39
Doxycycline 31 (−89 to 151), p=0.61 39 (−85 to 162), p=0.54
Azithromycin 1 (−123 to 124), p=0.99 −1 (−126 to 125), p=0.99
SGRQ total score
Moxifloxacin −2.25 (−8.60 to 4.09), p=0.49 −1.88 (−8.59 to 4.84), p=0.59
Doxycycline 0.88 (−5.30 to 7.06), p=0.78 1.02 (−5.28 to 7.31), p=0.75
Azithromycin −2.35 (−8.44 to 3.73), p=0.45 −2.29 (−8.43 to 3.86), p=0.47
Adherence to treatment. OR (95% CI)
Moxifloxacin 0.89 (0.05 to 15.09), p=0.94 0.74 (0.04 to 15.61), p=0.85
Doxycycline 0.64 (0.05 to 9.02), p=0.74 0.60 (0.04 to 9.68), p=0.72
Azithromycin 1.34 (0.07 to 26.06), p=0.84 2.42 (0.09 to 63.28), p=0.60
Exacerbation frequency. Relative risk (95% CI)
Moxifloxacin 1.36 (0.62 to 2.97), p=0.44 1.38 (0.62 to 3.10), p=0.43
Doxycycline 2.05 (0.98 to 4.29), p=0.06 2.07 (0.99 to 4.35), p=0.05
Azithromycin 0.83 (0.35 to 1.93), p=0.66 0.72 (0.30 to 1.71), p=0.45
Antibiotic resistance testing
Factor change in MIC
Moxifloxacin 4.82 (1.44 to 16.19), p=0.01
Doxycycline 3.74 (1.46 to 9.58), p=0.01
Azithromycin 6.23 (1.66 to 23.35), p=0.01
OR for resistant isolates
Moxifloxacin 2.03 (0.36 to 11.54, p=0.42
Doxycycline 5.77 (1.40 to 23.74, p=0·02)
Azithromycin 2.42 (0.61 to 9·62, p=0.21)
Sputum inflammatory markers
IL-1β (log10 pg/mL)
Moxifloxacin −0.25 (−0.63 to 0.14), p=0.21 −0.15 (−0.56 to 0.26), p=0.47
Doxycycline −0.10 (−0048 to 0.28), p=0.61 −0.03 (−0.43 to 0.37), p=0.88
Azithromycin 0.04 (−0.35 to 0.43), p=0.86 0.09 (−0.31 to 0.49), p=0.66
IL-6 (log10 pg/mL)
Moxifloxacin −0.16 (−0.50 to 0.18), p=0.37 −0.22 (−0.59 to 0.16), p=0.27
Doxycycline −0.21 (−0.56 to 0.13), p=0.22 −0.23 (−0.58 to 0.13), p=0.25
Azithromycin −0.19 (−0.43 to 0.27), p=0.65 −0.06 (−0.42 to 0.30), p=0.77
IL-8 (log10 pg/mL)
Moxifloxacin −0.26 (−0.72 to 0.19), p=0.26 −0.29 (−0.78 to 0.19), p=0.24
Doxycycline −0.11 (−0.55 to 0.34), p=0.64 −0.08 (−0.54 to 0.38), p=0.74
Azithromycin 0.00 (−0.46 to 0.46), p=1.00 0.02 (−0.45 to 0.49), p=0.94
*The results in the right hand column were adjusted for age, sex, smoking status, FEV1% predicted and prior exacerbation history. p Values were calculated using the Wald test.
IL, interleukin; MIC, mean inhibitory concentration; qPCR, quantitative PCR; SGRQ, St George’s Respiratory Questionnaire.
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fall in bacterial numbers on culture, it also had the highest inci-
dence of associated adverse events. There was evidence of an
increase in antibiotic resistance of the cultured isolates across all
treatment groups.
The primary endpoint of this study was total bacterial load,
as the sum of the load of all isolates from each sample. Most of
the bacteria isolated here were species classically considered to
be non-pathogenic in airway disease, and this is in keeping with
molecular studies of the airway microbiome which demonstrate
a diverse ﬂora dominated by ﬁrmicutes, including the
Streptococcus and Rothia spp predominant here.20 While previ-
ous exacerbation studies have focused on loads of the three
typical respiratory tract bacteria (S. pneumoniae, Haemophilus
inﬂuenzae or Moraxella catarrhalis),21 22 which appear to
increase at exacerbation,21 more recent investigation of the
overall airway microbiome during naturally occurring exacerba-
tions23 did not ﬁnd an increase in total bacterial numbers. As in
the gut, the lung microbiome is commensal and plays a role in
immune function;24 these non-pathogenic microorganisms are
therefore also important, and changes in their numbers are
Figure 2 Species breakdown of all cultured isolates (n=395) before and after treatment.
Figure 3 Boxplots for each treatment arm showing mean inhibitory concentrations (MICs) against that antibiotic compared with placebo before
and after 3 months of treatment. Note that MICs for all detected isolates are shown, and the number of isolates before and after treatment is not
necessarily comparable.
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likely to inﬂuence exacerbation susceptibility. We did not ﬁnd
any support for our hypothesis that antibiotic therapy reduces
total bacterial load in stable COPD, as well as potentially
improving clinical outcome measures. Airway inﬂammation also
did not change during treatment with any of these antibiotics
and this is in keeping with previous reports9 and despite known
anti-inﬂammatory effects of macrolide antibiotics. As discussed
below, patients in the doxycycline and moxiﬂoxacin arms suf-
fered more exacerbations during the study period, and given
that bacterial load,21 airway inﬂammation25 and quality of life1
all worsen signiﬁcantly at exacerbation this may have attenuated
any measured reductions. In addition, reductions in total bacter-
ial load may only persist for a short time after quinolone
therapy26 which might reduce the effectiveness of intermittent,
‘pulsed’ dosing regimens.12
Overall, however, antibiotic therapy did not appear to reduce
total bacterial load after 3 months of therapy when measured
either by culture or by 16S qPCR. The reduction in exacerba-
tion frequency observed elsewhere is therefore likely to be
mediated by other mechanisms. These may include either alter-
ing the background composition of the airway microbiome such
that exacerbation susceptibility is reduced, by making the airway
a less hospitable environment for the acquisition of new bacter-
ial strains that may potentially cause exacerbation27 or alterna-
tively by attenuating the rise in bacterial load when an
exacerbation occurs rather than reducing it in the stable state.
Further research is required to investigate these possibilities.
For the ﬁrst time, we have also directly analysed the measure-
ment techniques of 16S qPCR and quantitative culture in the
quantiﬁcation of the airway microbiome. qPCR detected
approximately 10 times as many bacteria as culture and,
although signiﬁcantly correlated, the wide variation between the
measured values limits their direct comparability. Culture-based
techniques are less sensitive than qPCR, and a normally cultiv-
able species may not grow on culture media even when it is
proved on sequencing to be the dominant organism in a
sample.20 These ﬁndings therefore support the move away from
culture-based to molecular techniques.
Administration of each antibiotic was associated with an MIC
increase of at least three times pretreatment values compared
with placebo, with a corresponding increase in clinical resistance
in those organisms for which this has been deﬁned; this sup-
ports ﬁndings from other short-term studies of antibiotic
therapy.28 However, in contrast to previous studies of antibiotics
in COPD focusing on resistance in speciﬁc pathogens,10 12 we
examined all isolates cultured from sputum, and we have exam-
ined resistance in greater detail. The information here therefore
provides a much better indication of resistance in the wider
airway microbiome. Macrolide resistance is rapidly inducible,
highly transferrable, and increasing in prevalence commensurate
with increasing macrolide prescriptions;13 resistance to quino-
lones and tetracyclines is also increasing globally.29 30 There is
evidence that commensal airway streptococci act as a reservoir
for S. pneumoniae resistance31 and the increased resistance
demonstrated here may therefore drive future antibiotic-resistant
disease. The approach of only examining resistance in those
species classically thought to be pathogenic may be too narrow.
There was an indication of a higher rate of treatment-related
adverse events and treatment discontinuation with moxiﬂoxacin
therapy than previously reported,12 although the types of events
Figure 4 Frequency of exacerbations experienced by patients during the study period, by treatment group.
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reported were similar. This may be related to the higher fre-
quency of administration here (4-weekly rather than 8-weekly)
than in the previous study. By contrast, azithromycin and doxy-
cycline were well tolerated. However, there is growing evidence
of increased cardiovascular risk with macrolides,11 32 as well as
high-frequency hearing loss,10 although the size and duration of
this trial were not sufﬁcient to examine these. Until these risks
are further evaluated, advice to exercise caution in patients with
cardiac risk factors33 still seems prudent.
There were no signiﬁcant changes seen in the other measures of
quality of life, lung function or adherence to therapy. There was an
apparent increase in exacerbations with doxycycline therapy,
although this was inﬂuenced by a small number of patients, and the
study period was relatively short for exacerbation detection.
Although the placebo group had a lower self-reported exacerbation
frequency than the active treatment arms, this was adjusted for in
the analysis. Furthermore our composite detection of exacerbations
(using diary cards and/or treatment) may have contributed to the
relatively higher recorded exacerbation frequency during the study.
This study was not powered to detect changes in exacerbation fre-
quency and this result should therefore be treated with caution.
There were a few limitations to this study. First, due to difﬁ-
culty in double-blinding each of the three treatment regimens in
a single trial, only one placebo was used and the trial was single
blind. The ﬁnal sample size was 50% lower than that initially
speciﬁed (99 compared with 200), and some patients were
unable to spontaneously expectorate sputum at their ﬁnal study
visit. This study was intentionally designed as a pilot explora-
tory study to assess airway bacterial changes with different anti-
biotics prior to a deﬁnitive study. Hence, the precision of the
estimates shown here cannot fully discount a reduction in
airway bacterial numbers of up to 0.9 log10 cfu/mL for moxi-
ﬂoxacin and 0.5 log10 cfu/mL for doxycycline and azithromycin.
Nevertheless, we have shown that larger reductions in airway
bacterial numbers (>1.0 log10, or 10-fold, cfu/mL) are unlikely.
While the study was terminated early due to constraints with
time lines, further recruitment would therefore have been
unlikely to alter these conclusions. Third, as an exploratory
study, this trial was not powered to detect changes in clinical
endpoints and therefore further trials will be needed regarding
the relative effectiveness of these antibiotics in practice.
In summary, we found no signiﬁcant changes in total bacterial
load with antibiotic therapy in this, the ﬁrst randomised,
blinded, placebo-controlled study to directly compare the use of
different antibiotics in stable COPD. We have also demonstrated
an increase in the degree and rate of resistance of cultured
airway bacteria following administration of these antibiotics.
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